Edition:
United States

Episurf Medical AB (EPISb.ST)

EPISb.ST on Stockholm Stock Exchange

6.80SEK
22 Sep 2017
Change (% chg)

-0.05kr (-0.73%)
Prev Close
6.85kr
Open
6.85kr
Day's High
7.00kr
Day's Low
6.65kr
Volume
41,926
Avg. Vol
58,336
52-wk High
15.63kr
52-wk Low
5.75kr

Latest Key Developments (Source: Significant Developments)

Episurf Medical Q2 pre-tax loss at SEK 13.0 million
Friday, 18 Aug 2017 02:30am EDT 

Aug 18 (Reuters) - EPISURF MEDICAL AB ::Q2 NET SALES SEK ‍622,897​ VERSUS SEK 469,380 YEAR AGO.Q2 PRE-TAX LOSS SEK ‍13.0​ MILLION VERSUS LOSS SEK 16.5 MILLION YEAR AGO.  Full Article

Episurf Medical Q2 pre-tax loss narrows to SEK 13 million
Friday, 18 Aug 2017 02:30am EDT 

Aug 18 (Reuters) - EPISURF MEDICAL AB :Q2 NET SALES SEK 622,897 VERSUS SEK 469,380 YEAR AGO.Q2 PRE-TAX LOSS SEK 13 MILLION VERSUS LOSS SEK 16.5 MILLION YEAR AGO.  Full Article

Episurf Medical becomes approved supplier to UK's Spire Healthcare
Thursday, 20 Jul 2017 02:30am EDT 

July 20 (Reuters) - EPISURF MEDICAL AB ::EPISURF MEDICAL HAS BECOME AN APPROVED SUPPLIER TO SPIRE HEALTHCARE, ONE OF THE UK'S LARGEST INDEPENDENT HOSPITAL PROVIDERS.  Full Article

Episurf Medical obtains further granted patent in Europe
Monday, 12 Jun 2017 07:30am EDT 

June 12 (Reuters) - EPISURF MEDICAL AB :EPISURF MEDICAL OBTAINS FURTHER GRANTED PATENT IN EUROPE.EUROPEAN PATENT OFFICE EPO HAS ANNOUNCED ITS INTENTION TO GRANT ANOTHER EUROPEAN PATENT FOR EPISURF MEDICAL.  Full Article

Episurf Medical names Pål Ryfors new CEO
Friday, 2 Jun 2017 10:25am EDT 

June 2 (Reuters) - EPISURF MEDICAL AB :EPISURF MEDICAL'S BOARD NAMES PÅL RYFORS NEW CEO AND APPOINTS NEW CFO.‍ANNOUNCES THAT VERONICA WALLIN IS APPOINTED CFO OF EPISURF MEDICAL​.  Full Article

Episurf Medical gets feedback from FDA on 513(g) request
Monday, 15 May 2017 08:45am EDT 

May 15 (Reuters) - EPISURF MEDICAL AB :EPISURF MEDICAL CONTINUES ITS COMMUNICATION WITH THE US FOOD AND DRUG ADMINISTRATION (FDA) REGARDING APPROPRIATE ROUTE FOR MARKET ACCEPTANCE IN THE US.EPISURF MEDICAL HAS NOW RECEIVED FEEDBACK FROM FDA REGARDING 513(G) REQUEST.FEEDBACK IS NOT DECISIVE AND OPENS UP VARIOUS ALTERNATIVES FOR EPISURF MEDICAL TO ASSESS; FURTHER INTERACTION WITH FDA HAS BEEN INITIATED.COMPANY EXPECTS TO COMPLETE ITS REVIEW AND REACH A DECISION BY Q3 OF 2017.  Full Article

Episurf Medical Q1 net sales at SEK 0.5 million
Monday, 15 May 2017 02:30am EDT 

May 15 (Reuters) - EPISURF MEDICAL AB ::Q1 NET SALES SEK 0.5 MILLION VERSUS SEK 0.4 MILLION YEAR AGO.Q1 OTHER OPERATING INCOME SEK 71,902 VERSUS SEK 0.6 MILLION YEAR AGO.  Full Article

Episurf Medical obtains further patent in the US
Monday, 8 May 2017 04:00am EDT 

May 8 (Reuters) - EPISURF MEDICAL AB ::EPISURF MEDICAL OBTAINS FURTHER GRANTED PATENT IN THE US.PATENT APPLICATION COVERS EPISURF MEDICAL'S SURGICAL DRILL GUIDE WITH A FUNCTIONALITY FOR DEPTH ADJUSTMENT.  Full Article

Episurf Medical obtains further granted patent in Australia
Thursday, 6 Apr 2017 04:40am EDT 

EPISURF MEDICAL AB :EPISURF MEDICAL OBTAINS FURTHER GRANTED PATENT IN AUSTRALIA.  Full Article

Episurf Medical rights issue subscribed for to 91.5 pct
Thursday, 16 Mar 2017 02:30am EDT 

Episurf Medical AB : Says final outcome of rights issue shows that offering was subscribed for by shareholders to about 91.5 pct .Receives about 109.5 million crowns before issue related costs.  Full Article

BRIEF-Episurf Medical Q2 pre-tax loss at SEK 13.0 million

* Q2 PRE-TAX LOSS SEK ‍13.0​ MILLION VERSUS LOSS SEK 16.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)